We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
+49.42%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$3.93B
AUM Growth
+$917M
Cap. Flow
-$94.3M
Cap. Flow %
-2.4%
Top 10 Hldgs %
73.9%
Holding
131
New
35
Increased
30
Reduced
17
Closed
20

Top Buys

Rank Stock Value
1
ARWR icon
Arrowhead Research
ARWR
+$64.3M
2
CRNX
Crinetics Pharmaceuticals
CRNX
+$54.4M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$26M
4
TNGX icon
Tango Therapeutics
TNGX
+$23.5M
5
MRUS
Merus
MRUS
+$18.5M

Top Sells

Rank Stock Value
1
CAVA icon
CAVA Group
CAVA
+$295M
2
CYTK icon
Cytokinetics
CYTK
+$54.7M
3
ARGX icon
argenx
ARGX
+$44.3M
4
HARP
Harpoon Therapeutics, Inc. Common Stock
HARP
+$14.8M
5
FOLD
Amicus Therapeutics
FOLD
+$13M

Sector Composition

Rank Sector Weight
1 Healthcare 50.26%
2 Consumer Discretionary 47.87%
3 Miscellaneous 1.15%
4 Technology 0.53%
5 Real Estate 0.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CAVA icon
1
CAVA Group
CAVA
$6.08B
$1.86B 47.31%
26,507,990
-5,500,000
-17% -$295M
LXRX icon
2
Lexicon Pharmaceuticals
LXRX
$841M
$282M 7.19%
117,553,284
– –
SRRK icon
3
Scholar Rock
SRRK
$5.87B
$200M 5.09%
11,259,438
– –
KYMR icon
4
Kymera Therapeutics
KYMR
$9.38B
$122M 3.1%
3,027,135
+496,400
+20% +$17.8M
ARWR icon
5
Arrowhead Research
ARWR
$10.8B
$86.8M 2.21%
3,036,668
+2,008,413
+195% +$64.3M
MORF
6
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$77.9M 1.98%
2,213,188
+75,000
+4% +$2.51M
APLS
7
DELISTED
Apellis Pharmaceuticals
APLS
$77.3M 1.97%
1,315,282
-106,064
-7% -$6.76M
SWTX
8
DELISTED
SpringWorks Therapeutics
SWTX
$69.7M 1.77%
1,415,348
-200,000
-12% -$9.25M
CRNX
9
DELISTED
Crinetics Pharmaceuticals
CRNX
$65.1M 1.66%
+1,390,477
New +$54.4M
ONC
10
BeOne Medicines Ltd
ONC
$39.4B
$63.3M 1.61%
404,782
+302
+0.1% +$48.6K
SLN
11
Silence Therapeutics
SLN
$768M
$60M 1.53%
2,779,619
-220,381
-7% -$4.79M
DYN icon
12
Dyne Therapeutics
DYN
$3.42B
$43.1M 1.1%
1,517,960
+300,000
+25% +$6.78M
RVMD icon
13
Revolution Medicines
RVMD
$43.1B
$42.5M 1.08%
1,318,649
-377,300
-22% -$11.2M
KURA icon
14
Kura Oncology
KURA
$985M
$41M 1.04%
1,919,884
+151,828
+9% +$2.95M
NMRA icon
15
Neumora Therapeutics
NMRA
$173M
$40.2M 1.02%
2,924,052
+371,350
+15% +$6M
KRRO icon
16
Korro Bio
KRRO
$200M
$37.7M 0.96%
419,226
+621
+0.1% +$33.9K
CYTK icon
17
Cytokinetics
CYTK
$9.72B
$35.5M 0.9%
506,584
-707,700
-58% -$54.7M
SLDB icon
18
Solid Biosciences
SLDB
$875M
$33.3M 0.85%
2,500,000
+1,590,781
+175% +$14.9M
IGMS
19
DELISTED
IGM Biosciences
IGMS
$29.7M 0.76%
3,080,422
-20,000
-0.6% -$232K
MDGL icon
20
Madrigal Pharmaceuticals
MDGL
$12B
$29.5M 0.75%
+110,507
New +$26M
CBIO
21
Crescent Biopharma
CBIO
$700M
$25.8M 0.66%
85,891
– –
WVE icon
22
Wave Life Sciences
WVE
$871M
$25M 0.64%
4,051,400
+1,044,000
+35% +$5.23M
PRTA icon
23
Prothena Corp
PRTA
$431M
$24.8M 0.63%
1,001,360
+500,000
+100% +$14.9M
XBI icon
24
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.3B
$23.7M 0.6%
+250,000
New +$23.2M
VERA icon
25
Vera Therapeutics
VERA
$2.39B
$21.8M 0.56%
+506,019
New +$18M
1
2 3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q1 2024 Portfolio in Review

As of Q1 2024, Artal Group held 131 positions worth $3.93B, up 30% from $3.01B the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Artal Group's Q1 2024 filing shows 35 new, 30 increased, 17 reduced and 20 closed positions. Its largest new stake was Crinetics Pharmaceuticals: 1,390,477 shares worth $65.1M. The largest sale was CAVA Group, an estimated $295M.

By sector, the portfolio is most concentrated in Healthcare at 50% of assets, down from 50% a quarter earlier, followed by Consumer Discretionary and Miscellaneous.

  • Artal Group's largest Q1 2024 buy was Crinetics Pharmaceuticals: 1,390,477 shares worth $65.1M.
  • Artal Group added most to Arrowhead Research in Q1 2024, an estimated $64.3M increase.
  • Artal Group's biggest Q1 2024 reduction was CAVA Group, cutting an estimated $295M.
  • Artal Group fully exited argenx in Q1 2024, selling an estimated $44.3M.
  • Artal Group's ten largest holdings make up 74% of its $3.93B portfolio in Q1 2024.
  • Artal Group opened 35 new positions and closed 20 in Q1 2024.
  • Artal Group's portfolio value rose 30% quarter-over-quarter to $3.93B.

Based on Artal Group's 13F filing for Q1 2024, filed 13 May 2024.